Publications by authors named "Roger Paredes"

Claim this Profile
I
Immune reconstitution in very advanced HIV patients treated with dolutegravir vs. darunavir-based triple antiretroviral therapy: the Advanz-4 randomized clinical trial.
Jose M Miro, Ferran Torres, Christian Manzardo, Eva Bonfill, Adrià Curran, Roger Paredes

Clin Microbiol Infect· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-COVID-19 condition patients' utilisation of healthcare resources after implementation of an integrated care unit.
José Ángel Vicente-Gómez, Martín de Muniategui Climente, Cora Loste, Saúl Barreales, Laura Ricou Ríos, Roger Paredes

Cost Eff Resour Alloc· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of virological outcomes after analytical interruption of antiretroviral therapy and HTI vaccination in early treated people with HIV-1._.
Lucia Bailón, Yovaninna Alarcón-Soto, José R Arribas, Adrian Curran, Anuska Llano, Roger Paredes

Commun Med (Lond)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HCV infection, risk factors and PrEP use among HIV-negative MSM and TW at a community health centre.
Àngel Rivero, Albert Dalmau-Bueno, Félix Pérez, P Coll, José M Cabrera, Roger Paredes

J Infect Public Health· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilizing HIV Proviral DNA to Assess for the Presence of HIV Drug Resistance.
Annemarie M Wensing, Charlotte Charpentier, Vincent Calvez, Francesca Ceccherini-Silberstein, Huldrych F Günthard, Roger Paredes

Clin Infect Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial.
Edward Weinstein, Roger Paredes, Annie Gardner, Mary Almas, Mary Lynn Baniecki

Lancet Infect Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Gut Microbiome and Its Resistome as Predictors of Clinical Infections and Phenotypic Antibiotic Resistance in Hematopoietic Stem Cell Transplant Recipients.
Jens C Nørgaard, Ramtin Z Marandi, Emma Elizabeth Ilett, Arda Gulay, Roger Paredes

J Infect Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial.
Jürgen K Rockstroh, Roger Paredes, Pedro Cahn, Jean-Michel Molina, Simiso M Sokhela

Clin Infect Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clusters of post-acute COVID-19 symptoms: a latent class analysis across 9 databases and 7 countries.
Kim López-Güell, Martí Català, Daniel Dedman, Talita Duarte-Salles, Raivo Kolde, Roger Paredes

J Clin Epidemiol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interactions between gut microbiota, plasma metabolome and brain function in the setting of a HIV cure trial.
Alessandra Borgognone, Anna Prats, Ashish Arunkumar Sharma, Ignacio Martinez-Zalacaín, Carles Soriano-Mas, Roger Paredes

Front Cell Infect Microbiol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strategies to Minimize Time From HIV Acquisition to ART Initiation: The Barcelona Early-cART Program.
Lucia Bailón, Yovaninna Alarcón-Soto, Angel Rivero, Pep Coll, Jorge Saz, Roger Paredes

Open Forum Infect Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and content validation of the Long COVID/ post-acute sequelae of COVID-19 (PASC) patient-reported outcome (PRO) instrument.
Dale Chandler, Benjamin Abramoff, Candace Bramson, Joseph C Cappelleri, Aishwarya Chohan, Roger Paredes

J Patient Rep Outcomes· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.
Ghady Haidar, Steven Thomas, Paul Loubet, Ross I Baker, Thomas Benfield, Roger Paredes

Lancet Infect Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of severe bacterial infections including TB before and after immediate or deferred antiretroviral therapy: A multicenter, prospective, cohort study.
Tomas O Jensen, Shweta Sharma, Anchalee Avihingsanon, Joseph Lutaakome, Indira Brar, Roger Paredes

Int J Infect Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of Long COVID in hospitalized individuals treated with remdesivir for acute COVID-19.
Mark Berry, Amanda M Kong, Roger Paredes, Julie Paone, Rohan Shah

Sci Rep· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial.
Ahmad Mourad, Gregory A Grandits, Lianne K Siegel, Nicole Engen, Christina Barkauskas, Roger Paredes

Clin Microbiol Infect· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Noncanonical HIV drug resistance mutations: need to close existing gaps.
Seth Inzaule, Michael R Jordan, Joseph Fokam, Raph L Hamers, Roger Paredes

AIDS· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phylogenetic analysis and structural studies of heteromeric acetyl-CoA carboxylase from the oleaginous Amazonian microalgae Ankistrodesmus sp.: Insights into the BC and BCCP subunits.
Andry Mercedes Mavila, Jhon Antoni Vargas, Eloy Condori, Erick Giancarlo Suclupe Farro, Adriano Alves Furtado, Roger Ruiz Paredes

J Struct Biol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Clinical and Genomic Features Associated with SARS-CoV-2 Reinfections.
Francisco Muñoz-López, Antoni E Bordoy, Francesc Català-Moll, Verónica Saludes, David Panisello Yagüe, Roger Paredes

Viruses· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antimicrobial regime for gut microbiota depletion in experimental mice models.
Laura Carrillo-Serradell, Alessandra Borgognone, Marc Noguera-Julian, Violeta Planells-Romeo, Lucía Aragón-Serrano, Roger Paredes

Methods Cell Biol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2025 update of the drug resistance mutations in HIV-1.
Annemarie M Wensing, Vincent Calvez, Francesca Ceccherini-Silberstein, Charlotte Charpentier, Huldrych F Günthard, Roger Paredes

Top Antivir Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-Cov-2 vaccination strategies in hospitalized recovered COVID-19 patients: a randomized clinical trial (VATICO Trial).
Sofía Sábato, Susana Benet, Angela J Rogers, Thomas A Murray, Melissa Skeans, Roger Paredes

Sci Rep· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting eEF1A reprograms translation and uncovers broad-spectrum antivirals against cap or mA protein synthesis routes.
Elisa Molina Molina, Joan Josep Bech-Serra, Eloi Franco-Trepat, Ignasi Jarne, Daniel Perez-Zsolt, Roger Paredes

Nat Commun· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial.
Sergio España-Cueto, Cora Loste, Gemma Lladós, Cristina López, José Ramón Santos, Roger Paredes

Nat Commun· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis